This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Emepronium
- DrugBank Accession Number
- DB13505
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 282.45
Monoisotopic: 282.221626326 - Chemical Formula
- C20H28N
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine 1,2-Benzodiazepine may increase the central nervous system depressant (CNS depressant) activities of Emepronium. Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Emepronium. Acetophenazine Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Emepronium. Aclidinium The risk or severity of adverse effects can be increased when Emepronium is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Emepronium. Agomelatine Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Emepronium. Alfentanil The risk or severity of adverse effects can be increased when Emepronium is combined with Alfentanil. Alimemazine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Emepronium. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Emepronium. Almotriptan Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Emepronium. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- A03CA30 — Emepronium and psycholeptics
- A03CA — Synthetic anticholinergic agents in combination with psycholeptics
- A03C — ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS
- A03 — DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- N05CX — Hypnotics and sedatives in combination, excl. barbiturates
- N05C — HYPNOTICS AND SEDATIVES
- N05 — PSYCHOLEPTICS
- N — NERVOUS SYSTEM
- Drug Categories
- Agents producing tachycardia
- Alimentary Tract and Metabolism
- Amines
- Anticholinergic Agents
- Autonomic Agents
- Central Nervous System Depressants
- Cholinergic Agents
- Drugs for Functional Gastrointestinal Disorders
- Drugs for Urinary Frequency and Incontinence
- Genito Urinary System and Sex Hormones
- Genitourinary Agents
- Hypnotics and Sedatives
- Muscarinic Antagonists
- Nervous System
- Neurotransmitter Agents
- Onium Compounds
- Parasympatholytics
- Peripheral Nervous System Agents
- Psycholeptics
- Quaternary Ammonium Compounds
- Urological Agents
- Urologicals
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Aralkylamines / Tetraalkylammonium salts / Organopnictogen compounds / Organic salts / Hydrocarbon derivatives / Organic cations
- Substituents
- Amine / Aralkylamine / Aromatic homomonocyclic compound / Diphenylmethane / Hydrocarbon derivative / Organic cation / Organic nitrogen compound / Organic salt / Organonitrogen compound / Organopnictogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 04QQ8SWA4U
- CAS number
- 27892-33-7
- InChI Key
- JEJBJBKVPOWOQK-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H28N/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20H,5,16H2,1-4H3/q+1
- IUPAC Name
- (4,4-diphenylbutan-2-yl)(ethyl)dimethylazanium
- SMILES
- CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 31386
- 3816
- ChEBI
- 135169
- ChEMBL
- CHEMBL2110805
- Wikipedia
- Emepronium_bromide
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 6.8e-06 mg/mL ALOGPS logP 0.15 ALOGPS logP 0.68 ChemAxon logS -7.7 ALOGPS Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 0 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 0 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 103.68 m3·mol-1 ChemAxon Polarizability 34.38 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Drug created at June 23, 2017 20:43 / Updated at June 12, 2020 16:53